Life Science Instrumentation Market Size & Forecast 2035
The global life science instrumentation market was valued at USD 70.36 billion in 2025 and is projected to rise from USD 75.92 billion in 2026 to USD 150.50 billion by 2035, expanding at a CAGR of 7.9% during 2026-2035.
Life science instrumentation comprises laboratory systems used to identify, separate, quantify, image, amplify, sequence, store and analyze biological samples. The market includes PCR platforms; DNA and RNA processing and sequencing instruments; chromatography, mass spectrometry and spectroscopy systems; flow cytometers; cell counters and imagers; clinical chemistry analyzers; centrifuges and incubators; filtration equipment; and cold-sample storage systems. Software, automation and instrument-linked services are included where they are sold as part of the analytical workflow; stand-alone reagents and general laboratory furniture are outside the core definition.
Key Takeaway
- 2025 market size: USD 70.36 billion
- 2035 market size: USD 150.50 billion
- Forecast CAGR: 7.9% from 2026 to 2035
- Largest 2025 product group: DNA and RNA processing and sequencing instruments, 24.4% or USD 17.17 billion
- Largest 2025 technology group: Spectroscopy, 23.5% or USD 16.53 billion
- Largest 2025 end user: Pharmaceutical and biotechnology companies, 42.6% or USD 29.97 billion
- Largest 2025 region: North America, 39.2% or USD 27.58 billion
- Fastest-expanding region: Asia-Pacific
Market Dynamics
Precision biology is changing the instrument mix
Instrument budgets are shifting toward systems that extract more information from limited samples. Proteomics, single-cell analysis, spatial biology, cell and gene therapy development and biomarker research require higher sensitivity, broader dynamic range and stronger data integration. Thermo Fisher’s May 2026 introduction of the Orbitrap Tribrid Apex and Orbitrap Excedion platforms illustrates the move toward instruments sold as connected discovery workflows rather than isolated analyzers. Bruker is following a similar path through timsTOF-based functional proteomics, high-field NMR and integrated multiomics.
This change favors vendors that combine hardware, sample preparation, software, libraries and support. It also raises switching costs: once a laboratory validates a regulated method, trains staff and connects an instrument to its data environment, the purchase decision extends beyond the original equipment price.
Automation is moving upstream into sample preparation
Sample preparation remains a major source of variability in flow cytometry, sequencing and mass-spectrometry workflows. In October 2026, Agilent introduced NovoStation to automate flow-cytometry sample preparation, while its September TapeStationDx launch extended automated nucleic-acid quality control into clinical NGS workflows. These releases point to a market in which preparation, analysis and interpretation are increasingly purchased together.
The commercial consequence is important: automation can shift spending from individual instruments to standardized platforms deployed across multiple laboratory sites. It also creates follow-on revenue from validated kits, plates, columns, service plans and software updates.
Academic demand remains uneven while translational applications advance
The market is not experiencing uniform expansion. Bio-Rad reported that second-quarter 2026 Life Science segment sales fell 4.1% year over year to USD 252.0 million, yet digital PCR instrument revenue increased by more than 20%. This split shows that constrained academic budgets can coexist with strong demand for technologies tied to oncology, rare-variant detection, cell and gene therapy and regulated molecular workflows.
Vendors are responding by emphasizing measurable throughput, reduced hands-on time and multi-application utilization. Instruments that support several departments or combine research and translational use have a stronger capital-approval case than single-purpose systems.
Installed-base economics are becoming decisive
Instrument manufacturers increasingly compete through uptime, consumable pull-through, application libraries, remote diagnostics and service coverage. A laboratory may keep a chromatography, mass-spectrometry or sequencing platform for seven to ten years, making service response and method continuity central to total cost. Vendors with direct field support, application scientists and local spare-parts capacity can protect pricing even when new-instrument demand slows.
Restraints: capital cost, utilization risk and data complexity
High-end systems can require dedicated facilities, trained operators, validation work and annual service agreements. Smaller laboratories may delay purchases when grant timing is uncertain or utilization cannot support the asset. Data-intensive instruments create another constraint: insufficient storage, compute capacity, cybersecurity controls and bioinformatics staff can reduce the practical throughput of otherwise advanced hardware.
Regulated laboratories also face a validation burden when software changes alter data processing. Vendors that provide traceable audit trails, controlled updates and long-term software support will be better positioned in clinical, biopharmaceutical and quality-control settings.
Market Segmentation Analysis
By Product Type
DNA and RNA processing and sequencing instruments led the market with 24.4% in 2025, equal to USD 17.17 billion. The segment includes library-preparation equipment, nucleic-acid extraction systems, sequencing platforms and associated quality-control instruments. Its lead reflects continued investment in oncology profiling, infectious-disease surveillance, rare-disease testing, biopharmaceutical development and population genomics. Clinical adoption increasingly depends on reproducible sample quality, which expands demand for instruments around the sequencer as well as for sequencing platforms themselves.
Clinical chemistry analyzers represented 18.7%, or USD 13.16 billion. These systems benefit from high routine-test volumes and replacement demand in hospital and reference laboratories. Growth is more closely tied to laboratory consolidation, automation and uptime than to entirely new test menus. Integrated analyzers that reduce operator intervention and connect with laboratory information systems have the clearest procurement advantage.
PCR instruments accounted for 17.6%, or USD 12.38 billion. Demand has moved beyond emergency respiratory testing toward digital PCR, oncology, transplant monitoring, reproductive health, environmental surveillance and bioprocess quality control. The strongest value creation lies in higher-precision systems and validated assay ecosystems rather than basic thermal cyclers.
Centrifuges and incubators held 12.4%, worth USD 8.72 billion. This mature category remains essential to cell culture, sample processing and biomanufacturing. Revenue is supported by replacement cycles, temperature control, contamination management and growth in cell-based research. Energy efficiency and remote monitoring increasingly influence multi-unit purchases.
Cell-counting and analysis instruments generated 9.8%, or USD 6.90 billion. Automated imaging, high-content analysis and flow-based systems are gaining ground as drug developers seek functional readouts rather than endpoint measurements alone. AI-assisted cell identification can expand throughput, but laboratories still require transparent quality controls and reviewable images.
By Technology
Spectroscopy held the largest technology share at 23.5%, equivalent to USD 16.53 billion in 2025. The category spans optical, infrared, Raman, atomic and magnetic-resonance techniques used in molecular characterization, quality control and structural biology. Investment is moving toward instruments that combine sensitivity with simplified workflows, including compact systems for laboratories without specialist operators.
Chromatography accounted for 20.8%, or USD 14.64 billion. Liquid and gas chromatography remain embedded in pharmaceutical development, biopharmaceutical characterization, food testing and environmental analysis. The commercial base extends beyond hardware to columns, consumables, software and qualification services, giving this segment a high recurring-revenue component.
PCR technology represented 18.6%, or USD 13.09 billion, while flow cytometry held 12.5%, or USD 8.80 billion. Flow cytometry is gaining from immunology, hematology, cell therapy and high-parameter research. Automated sample preparation and spectral capabilities are reducing workflow bottlenecks.
By Application
Research and drug discovery generated 37.8% of 2025 revenue, equal to USD 26.59 billion. Instrument spending is concentrated in target validation, biomarker discovery, screening, omics and mechanistic biology. Clinical diagnostics held 28.6%, or USD 20.12 billion, supported by routine chemistry, molecular testing, pathology and hospital-laboratory automation.
By End User
Pharmaceutical and biotechnology companies led with 42.6% in 2025, equal to USD 29.97 billion. Their spending covers discovery, process development, analytical development, quality control and manufacturing support. Contract research and development partners also buy instruments to serve multiple sponsors and shorten project timelines.
Academic and government research institutes accounted for 25.4%, or USD 17.87 billion. This segment remains scientifically influential but is sensitive to grant cycles and public budgets. Shared core facilities are becoming more important because they consolidate advanced systems and specialist staff.
Regional and Country-Level Analysis
North America
North America led the market with 39.2% in 2025, generating USD 27.58 billion. The United States alone represented 34.2% of global revenue, or USD 24.06 billion, supported by dense clusters of pharmaceutical companies, biotechnology firms, academic medical centers, core laboratories and contract research organizations. Capital allocation is selective: platforms tied to proteomics, digital PCR, cell therapy, spatial biology and clinical translation are outperforming general research equipment. UC Berkeley’s September 2026 multi-system high-field NMR order from Bruker shows that major institutions continue to fund shared research infrastructure when it supports several scientific programs.
Europe
Europe held 28.1% of the market, worth USD 19.77 billion in 2025. Germany represented 7.0% of global revenue, or USD 4.93 billion, reflecting its pharmaceutical, chemical-analysis, diagnostics and research-institute base. The United Kingdom held 5.2%, or USD 3.66 billion, with strong purchasing in genomics, proteomics, translational medicine and university core facilities. France contributed 4.2%, or USD 2.96 billion, supported by public research bodies, hospital laboratories and biopharmaceutical manufacturing.
European procurement increasingly weighs energy consumption, serviceability and data governance alongside analytical performance. The region also provides a launch pathway for regulated laboratory systems, illustrated by Agilent’s 2026 clinical NGS quality-control rollout and the expansion of digital-pathology instrumentation from selected European markets into the United States.
Asia-Pacific
Asia-Pacific accounted for 24.6%, or USD 17.31 billion in 2025, and is forecast to expand faster than the other major regions. China represented 9.2% of global revenue, or USD 6.47 billion. Local production, hospital laboratory expansion and biopharmaceutical capacity support demand, while procurement localization and price competition can limit imported-instrument growth.
Japan contributed 5.8%, or USD 4.08 billion. Its market is shaped by precision analytical engineering, pharmaceutical quality control, aging research infrastructure and strong domestic suppliers such as Shimadzu, JEOL and HORIBA. Japan is also a product-development center for chromatography, mass spectrometry and spectroscopy rather than only an end market.
Latin America
Latin America generated 4.4% of global revenue, or USD 3.10 billion in 2025. Brazil led regional demand through pharmaceutical production, agricultural biotechnology, public-health laboratories and university research. Mexico’s instrument base is supported by clinical laboratories, food testing and manufacturing quality control. Currency volatility and public tender timing can defer high-value installations, which increases demand for financing, refurbished systems and multi-year service packages.
Middle East and Africa
The Middle East and Africa held 3.7%, or USD 2.60 billion in 2025. Gulf countries are investing in genomics, precision medicine and national laboratory infrastructure, while South Africa has the region’s broadest established research and diagnostic base. Many markets remain dependent on distributors, so training, inventory and field-service capability determine which vendors can convert announced laboratory investment into sustained instrument utilization.
Competitive Landscape
Thermo Fisher Scientific
Thermo Fisher operates across life science solutions and analytical instruments, with products spanning mass spectrometry, chromatography, spectroscopy, electron microscopy, PCR, sequencing workflows, centrifugation, cold storage, laboratory automation and software. Its scale allows the company to connect discovery instruments with sample preparation, consumables and biopharma services. The May 2026 launch of Orbitrap Tribrid Apex and Orbitrap Excedion strengthened its high-resolution mass-spectrometry portfolio for proteomics and drug research. Thermo Fisher reports annual company revenue above USD 45 billion, although that total includes businesses outside this market.
Danaher Corporation
Danaher addresses the market through Beckman Coulter Life Sciences, SCIEX, Leica Microsystems, Molecular Devices, Phenomenex, Integrated DNA Technologies, Abcam and other operating companies. The portfolio covers flow cytometry, centrifugation, particle characterization, mass spectrometry, capillary electrophoresis, microscopy, high-content imaging, microplate detection and chromatography consumables. This multi-brand structure gives Danaher reach from research tools to bioprocess and diagnostic workflows. Its competitive advantage lies in connecting hardware with recurring consumables and continuous process improvement across a broad installed base.
Agilent Technologies
Agilent supplies liquid and gas chromatography, mass spectrometry, spectroscopy, cell-analysis systems, genomics quality control, laboratory automation, software, consumables and services. Fiscal 2025 company revenue was USD 6.95 billion. The Life Sciences and Diagnostics Markets group includes liquid chromatography and mass spectrometry platforms, cell and biomolecular analysis, pathology, companion diagnostics and genomics. Agilent’s 2026 launches—NovoStation, TapeStationDx and an AI module for BioTek cell imagers—show a strategy centered on automating preparation and interpretation around established instrument platforms.
Bio-Rad Laboratories
Bio-Rad competes in digital PCR, real-time PCR, electrophoresis, imaging, chromatography and cell biology. Its 2025 Life Science segment generated USD 1.021 billion. The company’s digital PCR portfolio includes the QX200 and QX600 families and the QX Continuum and QX700 series added through its Stilla Technologies acquisition and platform rollout. Second-quarter 2026 results revealed a clear product-mix signal: Life Science segment sales were USD 252.0 million and down 4.1% year over year, while digital PCR instrument revenue grew by more than 20%.
Recent Developments
- October 1, 2026 - Agilent Technologies: Introduced the NovoStation Sample Preparation System for automated flow-cytometry workflows. The launch targets variability and labor in the pre-analytical stage rather than adding another stand-alone analyzer.
- September 29, 2026 - Agilent Technologies: Introduced the Gen5 AI Cell Identification Module for BioTek automated cell imagers, adding machine-assisted classification to imaging workflows.
- September 21, 2026 - Agilent Technologies: Launched TapeStationDx systems for clinical NGS sample quality control, extending automated electrophoresis into in-vitro diagnostic workflows.
- September 21, 2026 - Bruker: Announced a multi-system high-field NMR order from the University of California, Berkeley, including 800 MHz-class instrumentation for biomolecular and materials research.
- September 2026 - Bruker: Advanced functional proteomics with timsUltra AIP and timsOmni workflows for drug development and disease-biology research.
- August 10, 2026 - Bruker: Announced a strategic collaboration with Atinary Technologies to advance self-driving laboratories, linking instrument operation with AI-guided experimental optimization.
- August 4, 2026 - Bruker: Announced a majority investment in MIMETAS, expanding its position in organ-on-chip and human physiology-relevant drug-discovery workflows.
- May 28, 2026 - Thermo Fisher Scientific: Unveiled the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers with AI-enabled analytics and scalable proteomics workflows.
- April 13, 2026 - Shimadzu Scientific Instruments: Launched the Nexis GC-2060 gas chromatograph and promoted the Nexera X4 UHPLC, emphasizing uptime, separation performance and high-speed analysis.
Strategic Key Takeaways
- Allocate capital by workflow, not instrument category. Sample preparation, software, consumables and service can determine productivity more than a headline sensitivity specification.
- Prioritize precision platforms with recurring pull-through. Digital PCR, advanced mass spectrometry, flow cytometry and sequencing quality control combine instrument revenue with assays, columns, plates and service.
- Treat academic demand and translational demand separately. Bio-Rad’s 2026 results show soft broad Life Science sales alongside more than 20% digital-PCR instrument growth.
- Build local service capacity in Asia-Pacific. Growth can be lost when installation, application training or spare-parts response does not match the speed of laboratory expansion.
- Design software updates for regulated continuity. Audit trails, controlled versions and validation support are becoming purchase criteria in clinical and biopharmaceutical laboratories.
- Use automation to attack pre-analytical variability. New systems are moving into preparation and quality control, where labor and error still constrain expensive downstream instruments.
- Measure installed-base value. Service attachment, consumable utilization, application expansion and upgrade conversion provide a clearer view of competitive strength than unit shipments alone.
Why Purchase the Report?
- To visualize the global Life Science Instrumentation- marketsegmentation based on Product, Technology, and region,as well as understandkey commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerousdata points of Life Science Instrumentationmarket-level with allsegments.
- PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key productsof all the major players.
The global Life Science Instrumentationmarketreport would provide approximately 53 tables, 54figures and 275 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

























































